NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $2.61 +0.05 (+1.95%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.54▼$2.6450-Day Range$1.92▼$2.6152-Week Range$1.46▼$3.26Volume1.23 million shsAverage Volume1.78 million shsMarket Capitalization$386.96 millionP/E RatioN/ADividend YieldN/APrice Target$4.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Xeris Biopharma alerts: Email Address Xeris Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside77.2% Upside$4.63 Price TargetShort InterestBearish7.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.96Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.39) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.71 out of 5 starsMedical Sector260th out of 936 stocksPharmaceutical Preparations Industry118th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.70% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 3.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Xeris Biopharma is -1.57. Previous Next 2.8 News and Social Media Coverage News SentimentXeris Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xeris Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows5 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.56% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.39) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Xeris Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Xeris Biopharma Stock (NASDAQ:XERS)Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Read More XERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XERS Stock News HeadlinesJuly 24 at 2:13 PM | finance.yahoo.comXERS Aug 2024 2.000 put (XERS240816P00002000)July 8, 2024 | proactiveinvestors.comXeris Biopharma unveils CEO succession plan, John Shannon to lead companyJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 3, 2024 | businesswire.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 3, 2024 | businesswire.comXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024May 30, 2024 | businesswire.comXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)May 30, 2024 | businesswire.comXeris to Participate in the Jefferies Global Healthcare ConferenceMay 10, 2024 | markets.businessinsider.comStrong Operational Performance and Promising Prospects Affirm Buy Rating for Xeris PharmaceuticalsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 10, 2024 | finance.yahoo.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comXeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst ChallengesMay 10, 2024 | finance.yahoo.comXeris Biopharma Holdings First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comQ1 2024 Xeris Biopharma Holdings Inc Earnings CallMay 9, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)May 9, 2024 | investorplace.comXERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | proactiveinvestors.comXeris Biopharma sees 1Q revenue jump on strength of product salesMay 9, 2024 | msn.comXeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17MMay 9, 2024 | finance.yahoo.comXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsSee More Headlines Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees377Year FoundedN/APrice Target and Rating Average Stock Price Target$4.63 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+75.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,260,000.00 Net Margins-37.58% Pretax Margin-38.13% Return on Equity-16,662.63% Return on Assets-19.58% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio1.81 Sales & Book Value Annual Sales$163.91 million Price / Sales2.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-52.60Miscellaneous Outstanding Shares148,260,000Free Float141,496,000Market Cap$389.92 million OptionableOptionable Beta2.72 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Paul R. Edick (Age 68)Chairman & CEO Comp: $1.21MMr. John P. Shannon (Age 62)President & COO Comp: $918.15kMr. Steven M. Pieper (Age 46)Chief Financial Officer Comp: $681.14kMs. Beth P. Hecht J.D. (Age 60)Chief Legal Officer & Corporate Secretary Comp: $695.44kDr. Kenneth E. Johnson Pharm. D. (Age 61)Pharm.D., Senior VP of Global Development & Medical Affairs Comp: $596.97kMs. Allison WeySenior Vice President of Investor Relations & Corporate CommunicationsMr. Kevin McCullochChief Commercial OfficerMore ExecutivesKey CompetitorsVeruNASDAQ:VERUZealand Pharma A/SNASDAQ:ZEALLongboard PharmaceuticalsNASDAQ:LBPHDynavax TechnologiesNASDAQ:DVAXArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 80,015 shares on 7/26/2024Ownership: 0.289%Allspring Global Investments Holdings LLCBought 15,929 shares on 7/26/2024Ownership: 0.011%Deltec Asset Management LLCSold 38,000 shares on 7/16/2024Ownership: 0.009%Rosalind Advisors Inc.Bought 300,000 shares on 7/12/2024Ownership: 2.105%Simplicity Wealth LLCBought 12,156 shares on 7/10/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $2.35 on January 1st, 2024. Since then, XERS shares have increased by 11.1% and is now trading at $2.61. View the best growth stocks for 2024 here. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The business earned $40.64 million during the quarter, compared to analysts' expectations of $41.56 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 16,662.63% and a negative net margin of 37.58%. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Xeris Biopharma's top institutional shareholders include Rosalind Advisors Inc. (2.10%), Bank of New York Mellon Corp (0.29%), Allspring Global Investments Holdings LLC (0.01%) and Deltec Asset Management LLC (0.01%). Insiders that own company stock include Paul R Edick, John Patrick Shannon Jr, John P Schmid and Steven Prestrelski. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN) and Dynavax Technologies (DVAX). This page (NASDAQ:XERS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
